Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
about
Newer antibacterial drugs for a new century.In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.The potential role of pemetrexed in gastrointestinal cancer.Current and novel antibiotics against resistant Gram-positive bacteriaEmerging agents to combat complicated and resistant infections: focus on ceftobiproleCeftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Putting fungi to work: harvesting a cornucopia of drugs, toxins, and antibiotics.Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infectionCANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbitsCommunity-associated meticillin-resistant Staphylococcus aureusGenotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infectionsSoft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysisPharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsMolecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unitNew antibiotics for bad bugs: where are we?Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.Ceftobiprole: First reported experience in osteomyelitis.In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infectionsMeta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study designCeftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).
P2860
Q30433333-D498381E-02D3-4A8E-9E79-A7727C713E30Q33559139-F9A4F22B-B9FB-4004-881A-16D953FE620CQ34187667-0A7482EF-D927-4CB9-80A9-68077E8A6250Q34417616-CBF83DC0-5D32-40B8-8616-503D910DB6BEQ34478074-09C96744-290F-470A-AE43-AC595B693EBDQ34722532-F2C36133-E909-4097-BBED-178451294B10Q35026521-EB697F12-6128-4C78-8A69-5AC91A26DBBCQ35026567-ED4DB3CC-7FBB-4AD5-B6EB-F5290E9A4C0DQ35117981-8A1D8676-7FE6-4C28-BCA5-68A8C3E64FCFQ35120203-F5B3CB45-53CB-4CB9-82B6-5C1F047F7077Q35598552-FCCC3F01-A358-40A3-9DC1-547B9B444292Q35941227-07D70DCB-7025-493B-999B-0EC5C89C83B8Q36396146-ADD678A5-5862-42D3-9C66-F3DF2AF8CAA9Q36438720-DBDA6F78-C3F2-40E8-A482-DC3B39B36BA6Q36489501-CB46B53D-AD2D-4739-9167-586983570B1BQ36785790-29847BBA-4768-4B91-B8BA-72B6BCAB8E03Q37115687-C834A14A-0E64-4E1D-B13F-BC58C9F00AC9Q37247602-04F7AE4D-1BE9-46BB-BE39-112027F89618Q37274751-E21657ED-78FD-411B-8804-C34029DE7EE9Q37392891-FE08E725-4E2D-4284-BD7F-16DAE7EFE65EQ37443022-80019408-5419-4DB0-9D0B-77BE8C718421Q38132217-421CA7EF-6976-48A9-B4EB-1117EAE20BA7Q40600643-49B9BB73-46E4-4CC8-9871-3D4FA34630DBQ41336401-8BC2D6A9-8D60-43CF-81F9-ED944204DE12Q42027484-707B8628-3645-4B37-A93D-68DD38EB5062Q42412528-2F708A56-3C74-471C-8E02-DB450708E7ACQ42444666-AA1C9774-D97F-44A0-9245-4FECA689B353Q42544277-0D1DF2E0-7D3E-42A8-84ED-5DD69F4A6947Q43065479-3899EEF4-8BA6-485F-AA2C-400FE3D17FD7
P2860
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Results of a double-blind, ran ...... sed by gram-positive bacteria.
@ast
Results of a double-blind, ran ...... sed by gram-positive bacteria.
@en
type
label
Results of a double-blind, ran ...... sed by gram-positive bacteria.
@ast
Results of a double-blind, ran ...... sed by gram-positive bacteria.
@en
prefLabel
Results of a double-blind, ran ...... sed by gram-positive bacteria.
@ast
Results of a double-blind, ran ...... sed by gram-positive bacteria.
@en
P2093
P2860
P1476
Results of a double-blind, ran ...... used by gram-positive bacteria
@en
P2093
Gary J Noel
Karen Amsler
Markus Heep
Richard S Strauss
Rienk Pypstra
P2860
P356
10.1128/AAC.00551-07
10.2217/14750708.5.1.37
P407
P577
2007-10-22T00:00:00Z